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To investigate he regulation of fl2AR expression i rat ventral prostate the effects of castration and testosterone replace- 
ment on the fl2AR were studied by ligand binding and Northern blot analysis. Orchidectomy depressed fl2AR number 
by 50% within 4 days and testosterone administration to 4-day castrates produced a rapid and complete recovery offl2AR 
number within 24 h. In contrast to receptor number, fl2AR mRNA levels did not change relative to total RNA following 
castration. However, during the testosterone r placement period fl2AR mRNA levels rose transiently, reaching a maxi- 
mum (3.5-fold) between 8and 12 h, and this increase in mRNA preceded the recovery in B2AR number in the membrane. 
Regulation of fl2AR gene expression by testosterone in the ventral prostate is thus complex and probably involves both 
transcriptional and post-transcriptional components. 
fl2-Adrenergic receptor; Androgen; Ventral prostate; mRNA 
1. INTRODUCTION 
Hormonal responsiveness of tissues can be 
regulated by several mechanisms, one of which is 
the dynamic regulation of the number of specific 
receptor sites on the cell surface. In the case of the 
/y-adrenergic receptor (flAR), a prototypic G- 
protein coupled receptor, both homologous and 
heterologous hormones can affect receptor 
number [1]. 
The rat ventral prostate contains one of the 
highest densities of /YEAR compared to other 
tissues [2,3], and recent evidence implicates both 
neurotransmitters and androgens in the develop- 
ment and function of the prostate and other ac- 
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cessory sex organs [4,5]. In addition, prostatic 
adenylate cyclase and/Y2AR number are known to 
be significantly altered by circulating androgens 
[2,6,7]; however, the mechanisms involved in this 
regulation of/Y2AR by testosterone are unknown. 
The cloning of the genes and cDNAs for several 
adrenergic receptors [8-11] now permits an ex- 
amination of the mechanisms involved in 
heterologous hormonal regulation of the members 
of this receptor family. 
2. MATERIALS AND METHODS 
Adult, male, Sprague-Dawley rats (Charles River Breeding 
Laboratories, Wilmington, MA) were maintained on a 12 h 
light:dark cycle. Dally subcutaneous injections of 1.0 mg 
testosterone propionate (4 mg/kg body wt in 0.1 ml vegetable 
oil) were as previously described [12]. At the time points in- 
dicated in the figures and legends, ventral prostate tissue was 
quickly removed from animals killed by decapitation, trimmed 
free of excess fat, and either flash-frozen i  liquid nitrogen, or 
minced finely on ice and used immediately. No differences in 
binding characteristics were observed between frozen and fresh 
tissue. Tissue was suspended in buffer (75 mM Tris, pH 7.5, 
12.5 mM MgCI2, 0.25 M sucrose containing 5/zg/ml soybean 
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trypsin inhibitor, 5#g/ml leupeptin and 15 #g/ml benzamidine) 
and homogenized in a motor-driven, glass-teflon homogenizer 
maintained on ice. The homogenate was filtered through two 
layers of cheesecloth and centrifuged at 40000 × g for 20 min. 
The crude membrane pellet was washed twice with buffer and 
resuspended. 
Binding of the #-adrenergic ligand [1251]cyanopindolol (CYP) 
was performed in homogenization buffer in the absence or 
presence of 1 #M alprenolol at 25°C for 90 min as previously 
described [13]. Competition binding assays to determine #AR 
subtype were performed with betaxolol (6'l-selective) and ICI 
118,551 ~2-selective). Binding parameters were estimated by 
nonlinear least squares curve fitting [14,15]. Protein concentra- 
tions were determined by the method of Bradford [16]. 
Total cellular RNA was isolated by the cesium chloride gra- 
dient method of Chirgwin [17]. RNA was denatured and elec- 
trophoresed through 1.2°70 agarose gels using the glyoxal 
procedure [18] and transferred to Biodyne (Pall Corp., Glen 
Cove, NY) membranes. Hybridizations with either the hamster 
#2-adrenergic receptor [8] or chicken ~-actin [19] cDNA probes 
were conducted as previously described [20]. These probes were 
labeled by nick translation with [a-32p]dCTP (3-8 x 
l0 s dpm/#g DNA). Following hybridization the filters were 
washed successively in 2 × SSC, 0.1% SDS at room 
temperature and 0.1 × SSC, 0.1% SDS at 55°C. 
3. RESULTS AND DISCUSSION 
Saturat ion binding studies with [125I]CYP in 
ventral prostate membranes from intact animals 
indicated a #AR density of  436 _+ 29 fmo l /mg 
membrane protein and a Kd for CYP binding of  
15 _+ 4 pM which did not change fol lowing castra- 
tion. Compet i t ion binding studies with the subtype 
selective antagonists betaxolol  (#l-selective) and 
ICI 118,551 (#E-selective) classified the receptors in 
the ventral prostate as being of  the #2 subtype (not 
shown). 
Fol lowing castrat ion, there was a steady decline 
in the number of/5'2AR in ventral prostate mem- 
branes to 50o70 of  control  ( -200  fmo l /mg protein) 
by 4 days (f ig. l ) .  Testosterone replacement pro-  
moted a rapid and complete recovery of  prostat ic 
#2AR (fig. 1). Within 24 h of  androgen administra-  
t ion, the receptor density returned to the level of  
the intact animal.  During the first 24 h period, 
when there were dramat ic  changes in receptor 
number,  there was no discernable tissue growth 
based on tissue weight (not shown). 
The decrease in prostatic #2AR observed fol low- 
ing castrat ion was not reflected in the steady-state 
mRNA levels analyzed by Northern blot hybridiza-  
t ion (fig.2). Four  days after castrat ion ~2AR 
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Fig.l. Change in /5'-adrenergic receptor number in ventral 
prostate membranes following castration (~') and testosterone 
replacement (~" + T). Male CD rats (250-300 g) were castrated 
as described in section 2 and killed at the indicated times. On 
day 4 of ~', daily injections of testosterone propionate (1.0 mg 
in 0.1 ml vegetable oil) were begun and animals were killed at 
the indicated time. 6-8 animals were used per point. Membrane 
preparations and [1251]CYP binding were performed as 
described in section 2. 
mRNA relative to total RNA was unchanged from 
levels in intact animals.  In other experiments 
equivalent amounts o f  #2AR mRNA were still 
detected on days 1, 2, 4 and 7 post-castrat ion ( ot 
shown). Testosterone replacement in 4-day 
castrates produced a rapid but transient increase in 
#eAR mRNA levels in the ventral prostate 
(f ig.3A). Peak induction in /32AR mRNA was 
found between 8 and 12 h. By compar ison,  actin 
mRNA levels appeared slightly elevated fol lowing 
castrat ion, but they remained relatively constant 
fol lowing testosterone (fig.3B). Relative to actin 
expression max imum increases in #2AR mRNA 
were est imated by densitometry to be 3.5-fold. 
These data demonstrate that #2AR levels in the 
rat ventral prostate are regulated by testosterone 
and that they display an immediate response to 
changes in androgen status. However,  it was unex- 
pected that the number o f  #2AR in the ventral 
prostate was not a direct function o f  the level o f  
#eAR transcripts.  Instead, when #2ARs declined 
fol lowing castrat ion, mRNA levels remained vir- 
tual ly unchanged. The process of  receptor turn- 
over may be sensitive to testosterone, such that 
fol lowing castrat ion the rate of  degradat ion of  the 
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Fig.2. Northern blot analysis of flz-adrenergic receptor mRNA 
levels in the ventral prostate of intact (c~) or 4-day castrated 
(~) rats. 20 ,ug of total cellular RNA were electrophoresed and 
blotted as described in section 2 and hybridized to a hamster 
~'2-adrenergic re eptor cDNA probe labeled with [a-32p]dCTP 
by nick-translation. The filter was exposed to Kodak XRP film 
for 4 days at -80°C. 
receptor was elevated. Alternat ively,  eff iciency of  
translat ion o f  the ~'zAR message could have been 
inf luenced by hormonal  status, as shown for a 
number of  other proteins [21-23]. At  present we 
are unable to dist inguish between these various 
possibi l it ies due to the l imitat ions of  this animal 
model .  
Dur ing the hormone replacement phase o f  these 
experiments,  testosterone promoted  a rapid and 
steady rise in prostat ic ~?2AR. With in 12 h, levels 
of  BzAR in testosterone-treated animals reached 
80% of  that in intact animals.  At  the same time 
there was an increase in f l2AR mRNA levels which 
peaked 8 to 12 h after init iat ion o f  hormone treat- 
ment. However,  this enhancement was not main-  
tained and it soon returned to the level of  the 
untreated control .  Similar f indings of  temporary  
transcr ipt ional  enhancement and mRNA ac- 
cumulat ion have been reported for other 
hormonal ly - regulated genes in vivo [24-26]. In 
some of  these cases, the transient nature of  the rise 
in mRNA levels has been ascribed to increased 
translat ional  eff iciency of  the newly synthesized 
message. In the case o f  the ~'2AR in the ventral 
prostate,  several events may be occurring. First,  
new mRNA may be synthesized in response to the 
androgen stimulus, and this might al low the cell to 
quickly recover the lost complement  of  receptors. 
Second, as a new steady-state l vel o f~2AR (which 
has been reported to have a relatively long half- l i fe 
[27]) is reached, mRNA synthesis declines. 
Our  results indicate that androgenic regulat ion 
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Fig.3. Northern blot analysis of mRNA levels for fl2-adrenergic 
receptor inrat ventral prostate after testosterone administration 
to 4-day castrates. Total cellular RNA (20,ug) was 
electrophoresed and blotted as described in section 2, and 
hybridized to a hamster ~'2-adrenergic receptor cDNA probe 
labeled with [te-32P]dCTP by nick-translation. Following 
exposure to Kodak XRP film, blots were stripped and reprobed 
with a 32p-labeled actin cDNA probe. The fold increase in 
~2-adrenergic receptor mRNA relative to actin mRNA was 
computed from densitometric tracings of the autoradiograms. 
of  ~'2AR is complex,  and that both transcr ipt ional  
and post-transcr ipt ional  components  are probab ly  
involved. The avai labi l i ty of  gene probes for 
several adrenergic receptor subtypes and model  
systems to study their expression should further 
our understanding of  the genetic regulat ion o f  this 
receptor family. 
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